Management of adenocarcinoma of unknown primary with a 5-fluorouracil- cisplatin chemotherapy regimen (CFTam)

Annals of Oncology

Volumn 10, Issue 11, 1999, Pages 1389-1392

  Lofts, F J ^a   Gogas, H ^a   Mansi, J L ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Chemotherapy; Primary; Unknown

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; TAMOXIFEN DERIVATIVE;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; STOMATITIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONFIDENCE INTERVALS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032779102     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008309204979     Document Type: Article

References (12)

1. Hainsworth JD, Greco FA. Treatment of patients with cancer of unknown primary site. NEJM 1993; 329: 257-263.
2. Lenzi R, Hess KR, Abbruzzese MC et al. Poorly differentiated carcinoma and poorly differentiated adenoearcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma. J Clin Oncol 1997; 15: 2056-66.
3. Stewart FJ, Tattersall MHN, Woods RL, Fox RM. Unknown primary adenoearcinoma: Incidence of over-investigation and natural history. BMJ 1979; 1: 1530-3.
4. Ellerbroek N, Holmes F, Singletary E et al. Treatment of patients with isolated axillary nodal metastates from an occult primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461-7.
5. Strnad CM, Grosh WM, Baxter MD. Peritoneal carcinomatosis of unknown primary site in women: A distinctive subset of adenoearcinoma. Ann Intern Med 1989; 111: 213-7.
6. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
7. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and enometrial carcinoma. Semin Oncol 1997; 24 (Suppl 1): 65-70.
8. Ercoli A, Scambia G, de Vincenzo R et al. Tamoxifen synergies the antiproliferative effect of cisplatin in human ovarian cancer cells enhancement of DNA platination as a possible mechanism. Cancer Lett 1996; 108: 7-14.
9. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 1987; 10: 82-5.
10. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site. Results of a 12-year experience. J Clin Oncol 1992; 10: 912-22.
11. Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272-80.
12. Ayoub JP, Hess KR, Abbruzzese MC et al. Unknown primary tumours metastatic to liver. J Clin Oncol 1998; 16: 2105-12.